DNER and acute myeloid leukemia: In this report, we demonstrate that a wide range of disparate AML subtypes are sensitive to growth inhibition in vitro following I-BET151 treatment, a specific inhibitor of BET proteins that we have previously shown to be of low toxicity in preclinical studies.6, 23 These data suggest the clinical utility of BET inhibition across a number of AML subtypes.